We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ekf Diagnostics Holdings Plc | LSE:EKF | London | Ordinary Share | GB0031509804 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.20 | -0.72% | 27.60 | 27.10 | 28.90 | 27.60 | 27.60 | 27.60 | 82,356 | 09:40:20 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Med, Dental, Hosp Eq-whsl | 52.61M | 2.35M | 0.0052 | 53.08 | 125.56M |
Date | Subject | Author | Discuss |
---|---|---|---|
19/3/2015 00:12 | it was a purchase taking him from 3.5% to 4.5% | cisk | |
18/3/2015 19:20 | Was that Zwanziger transaction just announced a purchase or disposal? Anyone know? | totaleclipse | |
18/3/2015 13:32 | Nothing was mentioned about PE approaches and no questions were asked at the end of the session. Contemplated asking but just assumed that the response would be that they couldn't comment on them. | cisk | |
18/3/2015 11:59 | Thank you Cisk, an interesting and balanced summary, and much appreciated. I would indeed prefer expectations to be set at realistic levels, if that then turns out to be conservative, then all the better and it will be rewarded accordingly. That aside, there is clearly a great deal more focus being deployed on the existing assets, and dare I say an air of confidence in delivering on some notable improvements/catalys The possibility of spinning off EKF Molecular is a very interesting option, but obviously one assumes this would be a bit further down the road, and could have been one of the aspects driving the Private Equity interest/approaches. Was there any discussions/further comments regarding those Private Equity approaches? | wan | |
18/3/2015 10:18 | Ekf Diagnostics Holding PLC Receives New Coverage from Analysts at Panmure Gordon (EKF) Posted by Taylor Nule on Mar 17th, 2015 Panmure Gordon initiated coverage on shares of Ekf Diagnostics Holding PLC (LON:EKF) in a research report sent to investors on Tuesday morning. The firm issued a buy rating and a GBX 39 Did anyone on here attend the Investor Briefing yesterday? | wan | |
17/3/2015 12:07 | Overall the results are not bad. It's obvious that they are targeting greater sales of specific product, and given that tactic succeeds, then I'm happy to continue holding. I may add later in the year if an uptrend that holds, comes about. Certainly looks like it's going in the right direction, IMHO. | andrewbaker | |
17/3/2015 08:31 | The new products catalogue is worth a look - | wan | |
16/3/2015 09:55 | worth 5p max, keeps on doing eggy farts | dlku | |
16/3/2015 09:18 | Well I did not think that I would get a chance to add at below 20p, which I have done twice this morning already, and ahead of the analysts briefing at 9:30am and I guess any new analysts consensus/price targets. Which is perhaps brave and could yet prove to be foolish, time will tell. I stand by my earlier suggestion for the share price having the potential to trade above 25p in the near term, which I see as a not too demanding target to achieve. | wan | |
16/3/2015 07:46 | Overall I like the new tone and focus. There is a lot of strategic change that is now sunk cost and effort, but not yet evidenced in the share price, but as the management humbly acknowledge, that will only come with delivery, which they appear very confident in achieving. The revelation of private equity interest/enquiries would imply there is a 'lot' of upside to be realized, which the management have decided that they can deliver and can better deliver in terms of shareholder value......I like that! | wan | |
16/3/2015 07:31 | And then it might be the year they admit they paid a lot of money for nothing | silverfern | |
25/2/2015 17:20 | Good find Wan - like Avacta, this could well be the year that EKF delivers on some interesting promises. | cisk | |
13/2/2015 08:21 | Personalised medicine and gene code sequencing and also blood samples instead of biopsies.Watch the biopsy part and think of the cost. Half a dozen health professionals involved in an invasive painful procedure. Then think of cell collectors and Pointman. | croasdalelfc | |
13/2/2015 07:53 | Cisk...I am usually up (and working) between 4am & 5am most mornings (inc Sunday)! I fancy that the perked up share price was due to more than my buying ;-) | wan | |
13/2/2015 07:24 | Hi Wan - couldn't sleep?! Thought it was your buying that perked up the share price ;-) Croasdalelfc - what BBC program are you referring to? | cisk | |
13/2/2015 05:38 | Cash flow looks like it should be very strong. I looked a little deeper generally, and have accumulated a few more over the last couple of weeks. | wan | |
12/2/2015 21:28 | Maybe the BBC program caused some peeps to wake up to the potential here? | croasdalelfc | |
04/2/2015 17:54 | Just having a first look at this and I have to say my first thought when I saw that they are running out of cash and they have changed broker was "Placing" Stuck them on my monitor but need to see what happens over the next couple of months. | salpara111 | |
02/2/2015 14:58 | Cisk, hope you're right but as you point out cash is getting very tight. If turnover is growing at very rapid rate then cash may well be required for working capital purposes. Not a bad thing in it's own right but obviously likely to be negative for the share price in the short term. Anyway I guess we will know in the next few weeks. Best regards SBP | stupidboypike | |
02/2/2015 14:32 | Pike, I would be both surprised and annoyed if this were true, if they aren't doing any acquisitions this year then why do they need the money? Net cash at year end was down to £2.4m from £5.2m at the half year - so looks like they are burning through just under half a mil per month; I note that debtors increased considerably so possibly working capital is tight? Also not sure when £1.4m is payable as final consideration for Diaspect. On the face of it they have maybe 6 months at the current run rate before net cash is zero; we all would hope that they bring in more business before then. I doubt that they would be able to get a placing to fly on the back of working capital purposes, besides there's no way any more shares should be issued if no deals are done. They need to hunker down, get everything working and build profits. Judging from the TU last week, management have got the message (we hope). | cisk | |
02/2/2015 14:02 | With a suggestion like that....don't tell them your name Pike! | wan | |
02/2/2015 13:43 | Call me cynical, but doesn't change of advisor normally mean, "placing on the way" ? I have these on my watch list and I do think they will come good over the next couple of years but I will wait and see if my placing suggestion has any legs before dipping my toe in. Best regards SBP | stupidboypike |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions